Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Stelara and Enbrel Chosen for IRA Price Negotiation

August 29th 2023

By Skylar Jeremias

Article

Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).

Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars

August 28th 2023

By Robert Zutaut, RPh

Article

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Cardinal Health's Dr Fran Gregory Reacts to First MS Biosimilar Approval

August 27th 2023

By Skylar Jeremias

Video

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, shares her reaction to the FDA approval of Tyruko (natalizumab-sztn), the first biosimilar approved to treat multiple sclerosis (MS).

Meta-Analysis Confirms Clinical Equivalence Between RA Biosimilars, Originators

August 26th 2023

By Skylar Jeremias

Article

A meta-analysis and systematic review of data on over 10,000 patients with rheumatoid arthritis (RA) found that etanercept, adalimumab, and infliximab biosimilars were clinically equivalent to their reference products.

FDA Approves First MS Biosimilar

August 25th 2023

By Skylar Jeremias

Article

The FDA approved its first biosimilar indicated for multiple sclerosis (MS), Sandoz’ Tyruko (natalizumab-sztn), a biosimilar referencing Tysabi (natalizumab).

The Top 5 Biosimilar Articles for the Week of August 21

August 25th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of August 21, 2023.

Biosimilar Teriparatide Improves BMD for Patients With Osteoporosis, Study Finds

August 24th 2023

By Justina Petrullo

Article

Biosimilar teriparatide improves bone mineral density (BMD) when patients with osteoporosis are treated for a year or more.

Reference and Biosimilar Adalimumab Appear to Share Biosimilarity

August 23rd 2023

By Justina Petrullo

Article

Data suggest that biosimilarity is demonstrated between reference and biosimilar adalimumab.

Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry

August 23rd 2023

By Skylar Jeremias

Article

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, published her opinions on the future of biosimilars in the United States, foreshadowing immense growth and a transformation of the US health care industry thanks to biosimilars.

Contributor: What’s Behind the Slow Uptake of Biosimilars in the US?

August 22nd 2023

By Dan Danielson, RPh, MS

Article

Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explains the remaining issues at play slowing down biosimilar uptake in the United States.